Aptose Biosciences, Inc.
APTO
APTO was delisted on the 1st of April, 2025.
64 hedge funds and large institutions have $278M invested in Aptose Biosciences, Inc. in 2020 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 32 increasing their positions, 11 reducing their positions, and 8 closing their positions.
1,045% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $135K
191% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 11
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
23% more capital invested
Capital invested by funds: $227M → $278M (+$51.7M)
10% more funds holding
Funds holding: 58 → 64 (+6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$11.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$7.39M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$5.75M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
+$5.72M |
| 5 |
CCM
Consonance Capital Management
New York
|
+$5.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$7.38M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$4.73M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$687K |
| 4 |
Renaissance Technologies
New York
|
-$656K |
| 5 |
Two Sigma Investments
New York
|
-$353K |
APTO Hedge Fund Activity: Q3 2020 in Review
64 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences, Inc. (APTO) for Q3 2020, worth a combined $278M — up 23% from $227M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new APTO positions and 8 closed out — a net gain of 6 holders — while 32 added to existing stakes and 11 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $11.5M. The largest seller was Opaleye Management, cutting an estimated $7.38M.
- 64 institutional investors held Aptose Biosciences, Inc. (APTO) as of Q3 2020, up from 58 in Q2 2020.
- Funds reported $278M of Aptose Biosciences, Inc. stock for Q3 2020, up 23% quarter-over-quarter.
- 14 funds opened new Aptose Biosciences, Inc. positions in Q3 2020 and 8 closed out, a net change of +6 holders.
- The largest Aptose Biosciences, Inc. buyer in Q3 2020 was Point72 Asset Management, an estimated $11.5M added.
- The largest Aptose Biosciences, Inc. seller in Q3 2020 was Opaleye Management, an estimated $7.38M sold.
Based on aggregated 13F filings for Q3 2020.